{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+lipid&page=2", "query": { "intervention": "intravenous lipid", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+lipid&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T22:29:37.403Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02591173", "title": "Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Autonomic Nervous System Disorders", "Pure Autonomic Failure", "Shy-Drager Syndrome", "Orthostatic Hypotension, Dysautonomic" ], "interventions": [ { "name": "Angiotensin-(1-7)", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 7, "start_date": "2016-02", "completion_date": "2020-07", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02591173" }, { "nct_id": "NCT02646475", "title": "Metabolic Effects of Angiotensin-(1-7)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Insulin Resistance", "Hypertension", "Metabolic Cardiovascular Syndrome" ], "interventions": [ { "name": "Angiotensin-(1-7)", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 26, "start_date": "2016-02", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646475" }, { "nct_id": "NCT05039619", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Acetaminophen/paracetamol", "type": "DRUG" }, { "name": "Diphenhydramine hydrochloride (HCl)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 40, "start_date": "2022-05-12", "completion_date": "2030-06-14", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 11, "location_summary": "Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039619" }, { "nct_id": "NCT07227207", "title": "A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alpha-1 Antitrypsin Deficiency (AATD)" ], "interventions": [ { "name": "TSRA-196", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tessera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2026-04-21", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 5, "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227207" }, { "nct_id": "NCT04201418", "title": "A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hereditary Transthyretin-mediated (ATTRv) Amyloidosis", "Polyneuropathy" ], "interventions": [ { "name": "Patisiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2019-12-18", "completion_date": "2022-05-24", "has_results": false, "last_update_posted_date": "2022-06-06", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 27, "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04201418" }, { "nct_id": "NCT02609984", "title": "Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Myxoid/Round Cell Liposarcoma", "Synovial Sarcoma", "Metastatic Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Locally Advanced Sarcoma", "Liposarcoma" ], "interventions": [ { "name": "CMB305", "type": "BIOLOGICAL" }, { "name": "atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2015-04-29", "completion_date": "2019-02-06", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 18, "location_summary": "Palo Alto, California • Santa Monica, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02609984" }, { "nct_id": "NCT05421858", "title": "A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia", "Candidiasis, Invasive" ], "interventions": [ { "name": "Fosmanogepix", "type": "DRUG" }, { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-12-11", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421858" }, { "nct_id": "NCT03894046", "title": "Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acinetobacter Baumannii-calcoaceticus Complex", "Hospital-acquired Bacterial Pneumonia", "Ventilator-associated Bacterial Pneumonia", "Bacteremia", "Colistin Resistant ABC" ], "interventions": [ { "name": "Sulbactam", "type": "DRUG" }, { "name": "Durlobactam", "type": "DRUG" }, { "name": "Colistin", "type": "DRUG" }, { "name": "Imipenem/Cilastatin 500 mg/500 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Entasis Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2019-09-05", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 5, "location_summary": "Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894046" }, { "nct_id": "NCT00880607", "title": "Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain Management", "Spinal Fusion", "Scoliosis" ], "interventions": [ { "name": "Intrathecal morphine", "type": "DRUG" }, { "name": "Extended Release Epidural Morphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 84, "start_date": "2008-12", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00880607" }, { "nct_id": "NCT00244816", "title": "Taxoprexin® Treatment for Advanced Eye Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Taxoprexin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Regent, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 22, "start_date": "2005-10", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-29T22:29:37.403Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244816" } ] }